Short Pulse and Q-switched ND-YAG Laser With Topical Carbon Versus Fractional CO2 Laser for Enlarged Facial Pores

Short Pulse and Q-switched ND-YAG Laser With Topical Carbon Versus Fractional CO2 Laser in Treatment of Enlarged Facial Pores: A Split-face Comparative Study

Facial pores are visible topographic features of the skin that reflect openings of pilosebaceous follicles, that may be enlarged causing distress to some individuals. Many patients desire treatment for this condition, which can be an early sign of skin aging. Therapeutic modalities include intense pulsed light, radiofrequency, dermabrasion, oral and topical retinoids, as well as chemical peeling. Lasers, as fractional CO2, short pulse and Q-switched Nd-YAG, can potentially be used in treatment of wide pores.

This study aims at the assessment and comparison of therapy with short pulsed and Q-switched Nd-YAG laser plus topical carbon with fractional CO2 laser in the management of wide facial pores.

Study Overview

• Status: Completed
• Conditions: Skin Lesion
• Intervention / Treatment: Device: short pulse and Q-switched ND-YAG laser with topical carbon; Device: fractional CO2 laser

Detailed Description

topical carbon cream will be applied to one side of the face in patients with wide facial pores, followed by 2 passes of short pulse 1064 ND:YAG laser, then one pass of Q-switched ND-YAG laser.

fractional CO2 laser will be performed to the other half of the face. the patients will receive 2 treatment sessions

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Egypt
  • Cairo, Egypt, 11562
    • Kasr Alainy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participants who are more than 18 years old with the large facial pores and are aware of their problem and seeking treatment

Exclusion Criteria:

• • Previous laser therapy, chemical peeling, microdermabrasion or cosmetic procedure for the face.

  • Patients with any contraindication to laser therapy such as photosensitive diseases, skin malignancies, patients on oral retinoids.
  • Keloid-forming tendency.
  • Local or systemic treatment for skin pores in the previous 3 months
  • Connective tissue disease or the use of immunosuppressive medications.
  • Pregnancy.
  • Present or past history of herpes labialis.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: short pulse and Q-switched ND-YAG laser with topical carbon	Device: short pulse and Q-switched ND-YAG laser with topical carbon; application of topical carbon cream, followed by two passes of short pulse 1064 ND-YAG, then one pass of Q-switched 1064 ND-YAG on one side of the face
Active Comparator: Fractional CO2 Laser	Device: fractional CO2 laser; single pass of fractional CO2 laser on the other side of the face

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
the percentage of decrease in size of enlarged facial pores assessed clinically and by dermoscopy	2 months

Collaborators and Investigators

• Sponsor: Cairo University

Study record dates

Study Major Dates

• Study Start (Actual): July 19, 2020
• Primary Completion (Actual): October 12, 2020
• Study Completion (Actual): October 12, 2020

Study Registration Dates

• First Submitted: July 4, 2020
• First Submitted That Met QC Criteria: July 9, 2020
• First Posted (Actual): July 14, 2020

Study Record Updates

• Last Update Posted (Actual): October 19, 2020
• Last Update Submitted That Met QC Criteria: October 13, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: las49

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes